Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>Concern has been raised in the rheumatological community regarding recent regulatory warnings that hydroxychloroquine used in the COVID-19 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation, or psychosis associated with hydroxychloroquine as used for rheumatoid arthritis (RA).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>New user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and US). RA patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine (active comparator) and followed up in the short (30-day) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation, and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HR), with estimates pooled where I<jats:sup>2</jats:sup>&lt;40%.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>918,144 and 290,383 users of hydroxychloroquine and sulfasalazine, respectively, were included. No consistent risk of psychiatric events was observed with short-term hydroxychloroquine (compared to sulfasalazine) use, with meta-analytic HRs of 0.96 [0.79-1.16] for depression, 0.94 [0.49-1.77] for suicide/suicidal ideation, and 1.03 [0.66-1.60] for psychosis. No consistent long-term risk was seen, with meta-analytic HRs 0.94 [0.71-1.26] for depression, 0.77 [0.56-1.07] for suicide/suicidal ideation, and 0.99 [0.72-1.35] for psychosis.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Hydroxychloroquine as used to treat RA does not appear to increase the risk of depression, suicide/suicidal ideation, or psychosis compared to sulfasalazine. No effects were seen in the short or long term. Use at higher dose or for different indications needs further investigation.</jats:p><jats:sec><jats:title>TRIAL REGISTRATION</jats:title><jats:p>Registered with EU PAS; Reference number EUPAS34497 (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.encepp.eu/encepp/viewResource.htm?id=34498">http://www.encepp.eu/encepp/viewResource.htm?id=34498</jats:ext-link>). The full study protocol and analysis source code can be found at <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine">https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine</jats:ext-link>.</jats:p></jats:sec><jats:sec><jats:title>WHAT IS ALREADY KNOWN ON THIS TOPIC</jats:title><jats:list list-type="bullet"><jats:list-item><jats:p>Recent regulatory warnings have raised concerns of potential psychiatric side effects of hydroxychloroquine at the doses used to treat COVID-19, generating concern in the rheumatological community</jats:p></jats:list-item><jats:list-item><jats:p>Serious psychiatric adverse events such as suicide, acute psychosis, and depressive episodes have been identified by the US Food and Drug Administration (FDA) adverse events reporting system and at case report level</jats:p></jats:list-item></jats:list></jats:sec><jats:sec><jats:title>WHAT THIS STUDY ADDS</jats:title><jats:list list-type="bullet"><jats:list-item><jats:p>This is the largest study on the neuro-psychiatric safety of hydroxychloroquine to date, including &gt;900,000 users treated for their RA in country-level or private health care systems in Germany, the UK, and the US</jats:p></jats:list-item><jats:list-item><jats:p>We find no association between the use of hydroxychloroquine and the risk of depression, suicide/suicidal ideation, or severe psychosis compared to sulfasalazine</jats:p></jats:list-item></jats:list></jats:sec><jats:sec><jats:title>HOW MIGHT THIS IMPACT ON CLINICAL PRACTICE</jats:title><jats:list list-type="bullet"><jats:list-item><jats:p>Our data shows no association between hydroxychloroquine treatment for RA and risk of depression, suicide or psychosis compared to sulfasalazine. These findings do not support stopping or switching hydroxychloroquine treatment as used for RA due to recent concerns based on COVID-19 treated patients.</jats:p></jats:list-item></jats:list></jats:sec></jats:sec>

Original publication

DOI

10.1101/2020.07.17.20156059

Type

Working paper

Publisher

Cold Spring Harbor Laboratory

Publication Date

22/07/2020